Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
- PMID: 32302707
- PMCID: PMC7194796
- DOI: 10.1016/j.phrs.2020.104791
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Conflict of interest statement
Declaration of Competing Interest This article has been conducted and written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment in
-
Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?".Pharmacol Res. 2020 Aug;158:104933. doi: 10.1016/j.phrs.2020.104933. Epub 2020 May 20. Pharmacol Res. 2020. PMID: 32445955 Free PMC article. No abstract available.
References
-
- Runfeng L., Yunlong H., Jicheng H., Weiqi P., Qinhai M., Yongxia S., Chufang L., Jin Z., Zhenhua J., Haiming J., Kui Z., Shuxiang H., Jun D., Xiaobo L., Xiaotao H., Lin W., Nanshan Z., Zifeng Y. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Pharmacol. Res. 2020;104761 doi: 10.1016/j.phrs.2020.104761. - DOI - PMC - PubMed
-
- Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/s0140-6736(20)30211-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources